Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 1225-1231, 2002;
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (31)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zehentner, B. K.
Right arrow Articles by Houghton, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zehentner, B. K.
Right arrow Articles by Houghton, R. L.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Cancer Diagnostics (since 2002)
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2002;48:1225-1231.)
© 2002 American Association for Clinical Chemistry, Inc.

Application of a Multigene Reverse Transcription-PCR Assay for Detection of Mammaglobin and Complementary Transcribed Genes in Breast Cancer Lymph Nodes

Barbara K. Zehentner1, Davin C. Dillon1, Yuqiu Jiang1, Jiangchun Xu1, Angela Bennington1, David A. Molesh1, XinQun Zhang1, Steven G. Reed1, David Persing1 and Raymond L. Houghtona1

1 Corixa, 1124 Columbia St., Seattle, WA 98104.

aAuthor for correspondence. Fax 206-754-5917; e-mail Houghton{at}corixa.com.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Background: Mammaglobin mRNA expression is found in 70–80% of primary and metastatic breast tumor biopsies. The potential breast tumor markers B305D, B726P, and {gamma}-aminobutyrate type A receptor {pi} subunit (GABA{pi}) complement the expression of mammaglobin. Collectively the expression profile of these four genes could be used as a diagnostic and prognostic indicator for breast cancer.

Methods: A multigene reverse transcription-PCR (RT-PCR) assay was established to detect the expression of mammaglobin, GABA{pi}, B305D, and B726P simultaneously. Specific primers and TaqMan® probes were used to analyze combined mRNA expression profiles in primary breast tumors and metastatic lymph node specimens.

Results: The multigene RT-PCR assay detected substantial expression signals in 27 of 27 primary tumor and 50 of 50 metastatic breast lymph node samples. Specificity studies demonstrated no significant expression signal in 27 non-breast cancer lymph nodes, in 22 various healthy tissue samples, or in 14 colon tumor samples.

Conclusion: The novel RT-PCR-based assay described here provides a sensitive detection system for disseminated breast tumor cells in lymph nodes. In addition, this multigene assay could also be used to test peripheral blood and bone marrow samples.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Mammaglobin, a highly glycosylated low-molecular-weight protein, is a homolog of rabbit uteroglobin and rat steroid-binding protein subunit C3 (1)(2) and is a member of the uteroglobin family with yet unknown functions. The known human family members [mammaglobin, lipophilin A and B, mammaglobin B (lipophilin C, lacryglobin), Clara cell 10-kDa protein] are localized in a dense cluster on chromosome 11q12.2 (3). Mammaglobin mRNA expression of has been described in 70–80% of primary and metastatic breast tumor biopsies (1)(4)(5)(6)(7). Furthermore, the mammaglobin gene has been used as a marker to detect circulating mammary carcinoma cells in peripheral blood by reverse transcription-PCR (RT-PCR)1 (8).

Although mammaglobin is a promising tumor marker, it is not universally expressed in breast cancers because these tumors are highly heterogeneous by gene expression profiling. Therefore, additional markers are needed for development of a sensitive assay to detect malignant breast cancer cells. Three genes, B305D, {gamma}-aminobutyrate type A receptor {pi} subunit (GABA{pi}), and B726P, have been identified by genetic subtraction, differential display, DNA microarray analysis, and real-time PCR as potential therapeutic and diagnostic targets in breast cancer. Recently we reported the complementary expression profile of these candidate genes in combination with mammaglobin in breast carcinomas (7). B305D is a novel gene that is located on chromosome 21q11.1, c1 region (AP001465.1). B305D cDNA has been isolated by differential display RT-PCR, and its sequence predicts a type II membrane protein.

The known gene GABA{pi} was recovered by PCR subtraction and found to be inversely expressed compared with B305D. GABA{pi} (U95367) belongs to the GABAA receptor family. Unlike other GABAA receptors, which are typically expressed in neuronal tissues, GABA{pi} shows low expression in lung, thymus, and prostate tissues and higher expression in the uterus (9). The cDNA designated as B726P (AL357148) was derived from PCR subtraction. B726P is a novel gene located on chromosome 10 with several different putative open reading frames yielded by mRNA splicing. One of these splice forms has recently been identified (10) by use of reactivity with autologous breast cancer patient sera and referred to as NY-BR-1.

In the present study we established a real-time multigene RT-PCR assay to simultaneously monitor the expression of these four breast cancer markers. The sensitivity and specificity of this assay were investigated using numerous primary breast tumors, metastatic lymph node, and healthy tissues.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
tissue samples
Primary breast cancer and healthy and tumor lymph node tissue samples were kindly provided by Dr. Elizabeth Repasky (Roswell Park Cancer Institute, Buffalo, NY) and Dr. Roberto Badaro (University of Bahia, Salvador, Brazil). Tissue samples were also obtained from National Disease Research Interchange. Lymph node cDNA samples were kindly provided by Dr. Michael Mitas (Medical University of South Carolina, Department of Surgery, Charleston, SC) and Dr. Timothy P. Fleming (Washington University School of Medicine, St. Louis, MO).

rna isolation and Cdna preparation
Total RNA was extracted from liquid-nitrogen-frozen tissue samples by homogenization in Trizol reagent (Invitrogen), and cDNA was prepared using oligo(dT) primer (Boehringer Mannheim) with SuperscriptTM II reverse transcriptase (Invitrogen) for 60 min at 42 °C.

pcr assay
A multigene real-time PCR assay was developed to detect the expression of the mammaglobin gene, GABA{pi}, B305D, and B726P simultaneously. The expression of single genes and their combined expression was measured by quantitative real-time PCR using the ABI 7700 PrismTM sequence detection system (Applied Biosystems). Specific primers and 6-carboxyfluorescein (FAM)-labeled TaqMan® probes were used in combination. Primers were designed to span intron-exon junctions to exclude genomic DNA from amplification. Primer concentrations that limited the reporter signal without decreasing the detected threshold cycle to avoid competition in the multigene PCR were determined.

The forward primer for mammaglobin was 5'-tgccatagatgaattgaaggaatg-3', and the reverse primer was 5'-tgtcatatattaattgcataaacacctca-3', both used at 100 nmol/L. The primer sequences for GABA{pi} were 5'-caattttggtggagaacccg-3' (forward) and 5'-gctgtcggaggtatatggtg-3' (reverse), used at 300 nmol/L and 50 nmol/L, respectively. For B305D amplification, 300 nmol/L forward primer 5'-tctgataaaggccgtacaatg-3' primer and 50 nmol/L reverse primer 5'-tcacgacttgctgtttttgctc-3' were used. For B726P, 100 nmol/L each of forward primer 5'-gcaagtgccaatgatcagagg-3' and reverse primer 5'-atatagactcaggtatacacact-3' were added to the PCR mixture. Actin expression was measured in separate reactions and used to normalize expression values; 300 nmol/L each of forward primer 5'-actggaacggtgaaggtgaca-3' and reverse primer 5'-cggccacattgtgaactttg-3' were used for actin amplification. For real-time detection, 4 pmol of each gene-specific TaqMan probe with the following sequences were used:

Mammaglobin: FAM-5'-tcttaaccaaacggatgaaactctgagcaatg-3'-6-carboxytetramethylrhodamine (TAMRA)

GABA{pi}: FAM-5'-catttcagagagtaacatggactacaca-3'-TAMRA

B305D: FAM-5'-atcaaaaaacaagcatggcctcacaccact-3'-TAMRA

B726P: FAM-5'-tcccatcagaatccaaacaagaggaagatg-3'-TAMRA

Actin: FAM-5'-cagtcggttggagcgagcatccc-3'-TAMRA.

Forty PCR cycles were performed with TaqMan 1000 Rxn PCR Core Reagents (part no. 430 4439; Applied Biosystems) using 0.0375 U/µL TaqGold; 1x Buffer A; 5 mM MgCl2; 0.2 mM each of dCTP, dATP, and dGTP; 0.4 mM dUTP; 0.01 U/µL AmpErase UNG; 80 nL/µL glycerol; 0.5 nL/µL gelatin; and 0.1 nL/µL Tween 20. PCR conditions were as follows: 1 cycle at 50 °C for 2 min, 1 cycle at 95 °C for 10 min, and 40 cycles at 95 °C for 15 s followed by 60 °C for 1 min and 68 °C for 1 min. For single-gene PCR, calibration curves were established using serial dilutions of plasmid DNA containing target gene cDNA sequence. For the multigene assay, combined copy numbers were determined by use of serial dilutions containing four plasmids to establish a calibration curve. TaqMan SDS analysis software was used to determine calibration curves and to calculate copy numbers. Final copy numbers were determined as mean values of triplicate PCR reactions and normalized per 1000 pg of actin. The mean variation within triplicates was 21% (range, 3–35%).

roc curve analysis
Rockit 0.9B Beta Version software (Dr. Charles E. Metz, Department of Radiology, The University of Chicago, Chicago, IL;http://www-radiology.uchicago.edu/krl/toppage11.htm) was used to analyze expression data obtained from pathology-positive breast cancer and healthy lymph node specimens. Detected copy numbers in lymph node samples for the mammaglobin, B305D, B726P, and GABA{pi} assays or the multigene RT-PCR assay, respectively, were processed for the 27 actually negative and the 50 actually positive cases. The generated output of true-positive fractions and the corresponding false-positive fractions was used for the construction of ROC curves as sensitivity and (1 - specificity).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
A panel of 27 primary breast tumor samples was used to compare the multigene real-time PCR assay with single-gene PCR. The multigene assay, which simultaneously detected the mammaglobin, B305D, B726P, and GABA{pi} genes, yielded a large expression signal for 27 of 27 tumor samples (Fig. 1B ) compared with mammaglobin expression alone, which detected 17 of these samples (Fig. 1A ). Table 1 further demonstrates the transcriptional complementation of the four target genes, with B305D being highly expressed in 16, GABA{pi} in 10, and B726P in 14 tumor specimens. All samples tested were detected positive with a combined expression signal by the multigene assay.



View larger version (47K):
[in this window]
[in a new window]
  		Figure 1. Comparison of mammaglobin expression and multigene signals detected in 27 primary breast cancer tumor cDNAs.

Mammaglobin expression alone was detected in 17 of 27 breast tumors (A). In the multigene assay, which detects mammaglobin, B305D, GABA{pi}, and B726P, 27 of 27 samples produced detectable expression signals (B). Multigene copy numbers were determined by construction of a calibration curve using a mixture of four plasmids containing inserts of mammaglobin, B305D, GABA{pi}, or B726P cDNA. Mean copy numbers were determined in triplicate PCR reactions. Actin copy numbers were detected in a separate PCR assay and used for normalization.


View this table:
[in this window]
[in a new window]
  		Table 1. Expression patterns1 of mammaglobin, B305D, GABA{pi}, and B726P in primary breast tumor specimens.

The expression profiles of B305D and GABA{pi} in the breast tumor samples showed an inverse relationship that was complementary. This led to the detection of 24 of 27 primary breast tumor samples based on the expression of these two genes alone. B726P expression showed an independent but additive profile compared with the other markers.

We then tested the cDNA from 50 pathology-positive metastatic breast cancer lymph node samples and 27 healthy or nonrelevant disease lymph node samples, respectively. All 50 metastatic breast cancer samples were detected with positive expression signals (Fig. 2 ), whereas nonbreast cancer-containing lymph node specimens showed no significant signals. Table 2 illustrates the complementary expression profiles of the four candidate genes in the 77 lymph node specimens tested.



View larger version (26K):
[in this window]
[in a new window]
  		Figure 2. Breast cancer lymph node analysis using the multigene real-time RT-PCR assay.

Combined copy numbers for mammaglobin, B305D, GABA{pi}, and B726P normalized per 1000 pg of actin were detected in 50 pathology-positive metastatic breast cancer lymph nodes and in 27 negative lymph nodes (24 healthy, 2 melanoma, and 1 lymphoma lymph node sample). Mean copy numbers were determined in triplicate PCR reactions and are shown in a logarithmic format. The range of copies/1000 pg of actin was 17.2–18 574.7 in metastatic breast cancer lymph nodes and 0–1.6 in negative lymph nodes.


View this table:
[in this window]
[in a new window]
  		Table 2. Positive expression signals for single-gene and/or multigene analyses in lymph node specimens, in colon tumor specimens, and in healthy tissues.

Substantial mammaglobin expression alone was detected in 40 metastatic breast cancer lymph node samples, ranging from 19.7 to 4.1 x 106 copies/1000 pg of actin. High expression of B305D was found in 36 (5–5 x 103 copies/1000 pg of actin), of GABA{pi} in 15 (11.7–830 copies/1000 pg of actin), and of B726P in 22 (7–4.9 x 104 copies/1000 pg of actin) of 50 pathology-positive breast cancer lymph node samples. No large expression signals were detected by the mammaglobin, B305D, GABA{pi}, B726P, or multigene RT-PCR assays in 24 healthy lymph node specimens, in 2 nodes containing melanoma, or in 1 node with evidence of lymphoma.

The multigene real-time PCR assay detected a positive signal for all 50 metastatic breast cancer lymph node specimens, ranging from 17.2 to 1.9 x 104 copies/1000 pg of actin. Similar to primary tumor samples, two genes in particular, B305D and GABA{pi}, added to the diagnostic sensitivity of mammaglobin detection in lymph node analysis. A combination of these three genes detected 50 of 50 lymph node breast metastases and 26 of 27 primary breast tumors evaluated. The inclusion of B726P enabled the detection of one primary tumor specimen. Moreover, parallel detection of the four genes enhanced the detection sensitivity for samples with low single-gene expression.

To assess the specificity of the multigene PCR assay described here, we tested a cDNA panel containing 14 colon tumor and 22 healthy tissue samples. Expression signals were detected in 0 of 14 colon tumors and in 4 of 22 healthy tissue samples (Table 2Up ). However, the low borderline signals detected in the four healthy tissue samples (esophagus, skin, trachea, and salivary gland) were only 2–6 copies/1000 pg of actin and were presumably attributable to low-level expression of mammaglobin in skin and of GABA{pi} and mammaglobin in salivary gland, trachea, and esophagus. No background expression was detected in bone marrow and peripheral mononuclear cells.

To compare the diagnostic performance of single markers and multimarker detection in lymph node analysis, we analyzed the expression data using Rockit 0.9B Beta Version software. ROC curves were established by plotting sensitivity vs (1 - specificity) to assess the accuracy of each assay (Fig. 3 ). The software was used to calculate ROC curve sensitivities and specificities and the corresponding area under the curve. The area under the ROC curve indicates the performance of an assay to separate the group being tested into actually negative and actually positive cases. A perfect test is represented by an area of 1, an excellent test by 0.9–1, and a good test by 0.8–0.9; 0.7–0.9 indicates moderate accuracy. Because of the perfect decision performance of the multigene assay, no actual curve could be constructed. ROC analysis of the multigene data produced an area value under curve of 1. The best performance for a single-gene expression assay was achieved by mammaglobin, with a ROC curve area value of 0.92. B305D expression data produced an area value of 0.84, which indicates good test performance. B726P RT-PCR, with an area under the curve of 0.78, and GABA{pi} RT-PCR, with an area under the curve of 0.77, can be categorized as assays with moderate accuracies.



View larger version (19K):
[in this window]
[in a new window]
  		Figure 3. ROC analysis of multigene and single-gene real-time RT-PCR expression data.

Expression data obtained from 27 true-negative and 50 true-positive lymph node specimens were analyzed using Rockit 0.9B Beta Version software (see Materials and Methods). Sensitivity was plotted against (1 - specificity) for single-gene and multigene RT-PCRs. The area under each ROC curve is indicative for the diagnostic accuracy of the applied test. The maximum curve area is covered by multigene assay analysis, indicating perfect decision performance in the sample population tested.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Lymph node staging provides the most important prognostic indicator in breast cancer (11). The presence of metastases in lymph nodes correlates directly to the risk of disease recurrence and patient survival. Conventionally, axillary dissection is used to collect lymph nodes for analysis. As an alternative, sentinel lymphadenectomy has been discussed as a less invasive strategy to identify lymphatic spread of metastatic cancer cells (5)(12)(13). Nodal metastases are identified by staining (hematoxylin or eosin) or immunohistochemical analysis for cytokeratin proteins (14). Inadequate sectioning in lymph node analysis can produce false-negative results by missing small metastatic foci. Approximately 30% of the patients diagnosed with pathologically negative lymph nodes develop recurrent disease. Because undetected micrometastases can be considered as a potential source for relapse of disease, more sensitive techniques for lymph node analysis have been discussed (5)(15)(16)(17). Molecular diagnostic approaches are potentially of higher sensitivity than immunohistochemistry. However, the application of RT-PCR for breast cancer cell detection is hampered by the lack of specific marker genes. Cytokeratins as epithelial cell marker genes have shown limited specificity for breast cancer cell detection (14)(18). Other potential tumor markers, in particular carcinoembryonic antigen, mucin 1, and mammaglobin, demonstrate higher specificity, but identify only a subset of tumor specimens (4)(5)(18)(19). No specific universal tumor marker has been identified to date because of the biological heterogeneity of breast carcinomas (20).

In this study we demonstrate the use of complementary expressed breast cancer genes for the development of a sensitive and specific RT-PCR assay to detect metastatic breast cancer cells. The multimarker assay described here increases the probability of detecting disseminated tumor cells and also provides the potential to characterize micrometastases on a molecular level. This could lead to improvements in prognosis and monitoring of disease, and possibly to individualized therapeutic strategies in the future.

For the future, intraoperative analysis of sentinel lymph nodes based on RT-PCR might even be possible. As a result of improved screening approaches, early detection of breast tumors with small diameters is increasing. Because the incidence of lymph node metastases is related to tumor size, for small tumors the value of routine axillary lymph node dissection, in consideration of the possibility of overtreatment and consequent morbidity, is a matter of much debate (21)(22)(23). The development of rapid quantitative RT-PCR protocols might provide the platform to realize highly sensitive intraoperative analysis of sentinel lymph nodes (24) and to gain prognostic information about the necessity of axillary dissection for disease control.

This study focused on lymph node analysis to evaluate the specificity and sensitivity of the assay. However, the multigene assay has potential applications in various tissues as a sensitive tool to detect breast tumor cells. Recently, we reported initial studies for these four genes individually (7) and in combination (25) to detect circulating breast tumor cells in peripheral blood samples.

Metastatic cells in bone marrow may also provide a high predictive value (26) for relapse of disease, independent of lymph node status. In addition, detection of cytokeratin-positive cells in the bone marrow of early- stage tumors has been suggested as a potential marker for early diagnosis of tumor dissemination (27). RT-PCR for mammaglobin has been shown to successfully detect bone marrow micrometastases (28). Mammaglobin gene expression is also a useful marker for detection of tumor cell contamination in leukaphereses, with potential application in autologous stem cell transplantation protocols for high-dose chemotherapy programs (29). Because of the increased sensitivity provided by the multigene assay compared with mammaglobin alone, we conclude that the method described here will be useful for the evaluation of peripheral blood, bone marrow, and leukapheresis samples for disseminated breast cancer cells.


   Acknowledgments
 
This work was supported in part by NIH Grants CA-75794 and CA-86673. We would like to acknowledge Dr. Roberto Badaro (University of Bahia, Salvador, Brazil) and Drs. Marcos Nolasco and Aristides Maltez Filho (Hospital Aristides Maltez, Salvador, Brazil) for kindly providing primary breast tumor tissues. We also thank Dr. Elizabeth Repasky (Roswell Park Cancer Institute, Buffalo, NY) for providing tissue samples, and Drs. Michael Mitas (Medical University of South Carolina, Department of Surgery, Charleston, SC) and Timothy P. Fleming (Washington University School of Medicine, St. Louis, MO) for providing lymph node cDNA samples.


   Footnotes
 
1 Nonstandard abbreviations: RT-PCR, reverse transcription-PCR; GABA{pi}, {gamma}-aminobutyrate type A receptor {pi} subunit; FAM, 6-carboxyfluorescein; and TAMRA, 6-carboxytetramethylrhodamine.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996;56:860-865.[Abstract/Free Full Text]
  2. Watson MA, Darrow C, Zimonjic DB, Popescu NC, Fleming TP. Structure and transcriptional regulation of the human mammaglobin gene, a breast cancer associated member of the uteroglobin gene family localized to chromosome 11q13. Oncogene 1998;16:817-824.[ISI][Medline] [Order article via Infotrieve]
  3. Ni J, Kalff-Suske M, Gentz R, Schageman J, Beato M, Klug J. All human genes of the uteroglobin family are localized on chromosome 11q12.2 and form a dense cluster. Ann N Y Acad Sci 2000;923:25-42.[ISI][Medline] [Order article via Infotrieve]
  4. Leygue E, Snell L, Dotzlaw H, Hole K, Troup S, Hiller-Hitchcock T, et al. Mammaglobin, a potential marker of breast cancer nodal metastasis. J Pathol 1999;189:28-33.[ISI][Medline] [Order article via Infotrieve]
  5. Min CJ, Tafra L, Verbanac KM. Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes. Cancer Res 1998;58:4581-4584.[Abstract/Free Full Text]
  6. Watson MA, Dintzis S, Darrow CM, Voss LE, DiPersio J, Jensen R, et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res 1999;59:3028-3031.[Abstract/Free Full Text]
  7. Houghton RL, Dillon DC, Molesh DA, Zehentner BK, Xu JC, Jiang J, et al. Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells. Mol Diagn 2001;6:79-91.[ISI][Medline] [Order article via Infotrieve]
  8. Zach O, Kasparu H, Krieger O, Hehenwarter W, Girschikofsky M, Lutz D. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction for mammaglobin mRNA. J Clin Oncol 1999;17:2015-2019.[Abstract/Free Full Text]
  9. Hedblom E, Kirkness EF. A novel class of GABAA receptor subunit in tissues of the reproductive system. J Biol Chem 1997;272:15346-15350.[Abstract/Free Full Text]
  10. Jager D, Stockert E, Gure AO, Scanlan MJ, Karbach J, Jager E, et al. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res 2001;61:2055-2061.[Abstract/Free Full Text]
  11. Perez-Mesa CM. Gross and microscopic pathology. Donegan WL Spratt JS eds. Cancer of the breast 1995:267-269 WB Saunders Philadelphia. .
  12. Noguchi M, Tsugawa K, Bando E, Kawahara F, Miwa K, Yokoyama K, et al. Sentinel lymphadenectomy in breast cancer: identification of sentinel lymph node and detection of metastases. Breast Cancer Res Treat 1999;53:97-104.[ISI][Medline] [Order article via Infotrieve]
  13. Whitworth P, McMasters KM, Tafra L, Edwards MJ. State-of-the-art lymph node staging for breast cancer in the year 2000. Am J Surg 2000;180:262-267.[ISI][Medline] [Order article via Infotrieve]
  14. Kostler WJ, Brodowicz T, Hejna M, Wiltschke C, Zielinski C. Detection of minimal residual disease in patients with cancer: a review of techniques, clinical implications, and emerging therapeutic consequences. Cancer Detect Prev 2000;24:376-403.[ISI][Medline] [Order article via Infotrieve]
  15. Mori M, Mimori K, Inoue H, Barnard GF, Tsuji K, Nanbara S, et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1995;55:3417-3420.[Abstract/Free Full Text]
  16. Ooka M, Sakita I, Fujiwara Y, Tamaki Y, Yamamoto H, Aihara T, et al. Selection of mRNA markers for detection of lymph node micrometastases in breast cancer patients. Oncol Rep 2000;7:561-566.[ISI][Medline] [Order article via Infotrieve]
  17. Pantel K, von Kneb el Doeberitz M. Detection and clinical relevance of micrometastatic cancer cells. Curr Opin Oncol 2000;12:95-101.[ISI][Medline] [Order article via Infotrieve]
  18. Zippelius A, Pantel K. RT-PCR-based detection of occult disseminated tumor cells in peripheral blood and bone marrow of patients with solid tumors. Ann N Y Acad Sci 2000;906:110-123.[ISI][Medline] [Order article via Infotrieve]
  19. Mitas M, Mikhitarian K, Walters C, Baron PL, Elliott BM, Brothers TE, et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer 2001;93:162-171.[ISI][Medline] [Order article via Infotrieve]
  20. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.[Medline] [Order article via Infotrieve]
  21. Sakorafas GH, Tsiotou AG, Balsiger BM. Axillary lymph node dissection in breast cancer. Acta Oncol 2000;39:455-466.[ISI][Medline] [Order article via Infotrieve]
  22. Lindahl T, Engel G, Ahlgren J, Klaar S, Bjohle J, Lindman H, et al. Can axillary dissection be avoided by improved molecular biological diagnosis?. Acta Oncol 2000;39:319-326.[ISI][Medline] [Order article via Infotrieve]
  23. Cserni G. Axillary staging of breast cancer and the sentinel node. J Clin Pathol 2000;53:733-741.[Abstract/Free Full Text]
  24. Godfrey TE, Raja S, Hughes S, Finkelstein SD, Luketich JD. Detection of occult micrometastases using intraoperative, quantitative RT-PCR [Abstract]. Clin Chem 2001;47:A103.
  25. Zehentner BK, Dillon DC, Jiang J, Xu JC, Badaro R, Zhang X, et al. A multigene real-time PCR assay for the detection of complementary transcribed genes in breast cancer [Abstract]. Clin Chem 2001;47:A129.
  26. Janni W, Hepp F, Rjosk D, Kentenich C, Strobl B, Schindlbeck C, et al. The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer 2001;92:46-53.[ISI][Medline] [Order article via Infotrieve]
  27. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or II breast cancer. N Engl J Med 2000;342:525-533.[Abstract/Free Full Text]
  28. Ooka M, Tamaki Y, Sakita I, Fujiwara Y, Yamamoto H, Miyake Y, et al. Bone marrow micrometastases detected by RT-PCR for mammaglobin can be an alternative prognostic factor of breast cancer. Breast Cancer Res Treat 2001;67:169-175.[ISI][Medline] [Order article via Infotrieve]
  29. Leone F, Perissinotto E, Viale A, Cavalloni G, Taraglio S, Capaldi A, et al. Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction. Bone Marrow Transplant 2001;27:517-523.[ISI][Medline] [Order article via Infotrieve]



The following articles in journals at HighWire Press have cited this article:


Home page
 JCOHome page
T. B. Julian, P. Blumencranz, K. Deck, P. Whitworth, D. A. Berry, S. M. Berry, A. Rosenberg, A. B. Chagpar, D. Reintgen, P. Beitsch, et al.
Novel Intraoperative Molecular Test for Sentinel Lymph Node Metastases in Patients With Early-Stage Breast Cancer
J. Clin. Oncol., July 10, 2008; 26(20): 3338 - 3345.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. Lacroix
Significance, detection and markers of disseminated breast cancer cells
Endocr. Relat. Cancer, December 1, 2006; 13(4): 1033 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Xenidis, M. Perraki, M. Kafousi, S. Apostolaki, I. Bolonaki, A. Stathopoulou, K. Kalbakis, N. Androulakis, C. Kouroussis, T. Pallis, et al.
Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer Patients
J. Clin. Oncol., August 10, 2006; 24(23): 3756 - 3762.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. A. Smirnov, B. W. Foulk, G. V. Doyle, M. C. Connelly, L. W.M.M. Terstappen, and S. M. O'Hara
Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas.
Cancer Res., March 15, 2006; 66(6): 2918 - 2922.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
S Abdul-Rasool, S H Kidson, E Panieri, D Dent, K Pillay, and G S Hanekom
An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes.
J. Clin. Pathol., March 1, 2006; 59(3): 289 - 297.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
W F Symmans, D J Fiterman, S K Anderson, M Ayers, R Rouzier, V Dunmire, J Stec, V Valero, N Sneige, C Albarracin, et al.
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding
Endocr. Relat. Cancer, December 1, 2005; 12(4): 1059 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
J. Backus, T. Laughlin, Y. Wang, R. Belly, R. White, J. Baden, C. J. Min, A. Mannie, L. Tafra, D. Atkins, et al.
Identification and Characterization of Optimal Gene Expression Markers for Detection of Breast Cancer Metastasis
J. Mol. Diagn., August 1, 2005; 7(3): 327 - 336.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. M. Reinholz, A. Nibbe, L. M. Jonart, K. Kitzmann, V. J. Suman, J. N. Ingle, R. Houghton, B. Zehentner, P. C. Roche, and W. L. Lingle
Evaluation of a Panel of Tumor Markers for Molecular Detection of Circulating Cancer Cells in Women with Suspected Breast Cancer
Clin. Cancer Res., May 15, 2005; 11(10): 3722 - 3732.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. L. Ferris, L. Xi, S. Raja, J. L. Hunt, J. Wang, W. E. Gooding, L. Kelly, J. Ching, J. D. Luketich, and T. E. Godfrey
Molecular Staging of Cervical Lymph Nodes in Squamous Cell Carcinoma of the Head and Neck
Cancer Res., March 15, 2005; 65(6): 2147 - 2156.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Mitas, J. S. Almeida, K. Mikhitarian, W. E. Gillanders, D. N. Lewin, D. D. Spyropoulos, L. Hoover, A. Graham, T. Glenn, P. King, et al.
Accurate Discrimination of Barrett's Esophagus and Esophageal Adenocarcinoma Using a Quantitative Three-Tiered Algorithm and Multimarker Real-time Reverse Transcription-PCR
Clin. Cancer Res., March 15, 2005; 11(6): 2205 - 2214.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
B. K. Zehentner, D. H. Persing, A. Deme, P. Toure, S. E. Hawes, L. Brooks, Q. Feng, D. C. Hayes, C. W. Critichlow, R. L. Houghton, et al.
Mammaglobin as a Novel Breast Cancer Biomarker: Multigene Reverse Transcription-PCR Assay and Sandwich ELISA
Clin. Chem., November 1, 2004; 50(11): 2069 - 2076.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. N. Span, E. Waanders, P. Manders, J. J.T.M. Heuvel, J. A. Foekens, M. A. Watson, L. V.A.M. Beex, and F. C.G.J. Sweep
Mammaglobin Is Associated With Low-Grade, Steroid Receptor-Positive Breast Tumors From Postmenopausal Patients, and Has Independent Prognostic Value for Relapse-Free Survival Time
J. Clin. Oncol., February 15, 2004; 22(4): 691 - 698.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
E. Floyd and T. M. Mcshane
Development and Use of Biomarkers in Oncology Drug Development
Toxicol Pathol, January 1, 2004; 32(1_suppl): 106 - 115.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Stathopoulou, A. Gizi, M. Perraki, S. Apostolaki, N. Malamos, D. Mavroudis, V. Georgoulias, and E. S. Lianidou
Real-Time Quantification of CK-19 mRNA-Positive Cells in Peripheral Blood of Breast Cancer Patients Using the Lightcycler System
Clin. Cancer Res., November 1, 2003; 9(14): 5145 - 5151.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (31)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zehentner, B. K.
Right arrow Articles by Houghton, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zehentner, B. K.
Right arrow Articles by Houghton, R. L.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Cancer Diagnostics (since 2002)
Right arrow Proteomics and Protein Markers

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS